(NBC News) – The Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical’s ADHD drug Vyvanse and its generic versions by about 24% to address the medicine’s ongoing shortage in the United States.

The raised production limit follows the Food and Drug Administration’s request in July, the DEA said in a notice on Tuesday. (Read More)